Today: 25 May 2026
Browse Category

NASDAQ:CRNX 26 September 2025 - 7 January 2026

Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025)

Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025)

Crinetics Pharmaceuticals shares fell about 8% Thursday after a regulatory filing disclosed Chief Medical and Development Officer Dr. Dana Pizzuti will step down December 31. She will transition to a Strategic Regulatory and Development Advisor role in early 2026. The stock traded in the low-to-high $40s as investors reacted to the leadership change.
18 December 2025
·
Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Electronic Arts shares jumped 15% after agreeing to a $55 billion buyout led by Saudi Arabia’s PIF, offering $210 per share. Crinetics Pharmaceuticals soared 28% as the FDA approved its oral acromegaly drug. QMMM Holdings surged 19% before the SEC halted trading over suspected manipulation. Scholar Rock gained 12% despite an FDA delay for its spinal atrophy drug.
29 September 2025
·····
Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Crinetics Pharmaceuticals shares surged 28% to around $46 on Sept. 26 after the FDA approved its first drug, Palsonify, for acromegaly. Trading volume spiked nearly tenfold amid heavy short-covering. The company plans to launch Palsonify in October at a $290,000 annual list price. Crinetics holds $1.2 billion in cash and no debt, with analysts raising price targets following the approval.
26 September 2025
··

Stock Market Today

  • West Pharmaceutical Services (WST) Valuation Review Amid Recent Share Momentum
    May 25, 2026, 5:46 PM EDT. West Pharmaceutical Services (WST) shares have risen nearly 29% over three months and delivered a 54% total shareholder return in one year, reflecting solid market momentum. Trading at $316.42, WST sports a $22.35 billion market capitalization, supported by $3.22 billion in annual revenue and $542.7 million net income from its injectable drug packaging business. Analysts highlight a 9.6% undervaluation, with a fair value estimate of $349.85 driven by growth in GLP-1 drug components and biologics high-value packaging. Despite longer-term mixed returns and risks like tariff pressure and demand fluctuations, WST's expanding contract services and improved earnings mix underpin positive outlooks. Investors weigh if current prices reflect future growth prospects or present a buying opportunity.

Latest articles

NIO stock closes flat as market looks ahead to post-earnings move

NIO stock closes flat as market looks ahead to post-earnings move

25 May 2026
NIO shares closed down 7.14% at $5.20 on Friday, despite U.S. markets trading higher. The New York Stock Exchange will remain closed Monday for Memorial Day, with trading set to resume Tuesday. NIO reported first-quarter revenue of $3.70 billion and delivered 83,465 vehicles, but investors remain cautious as competition in China’s EV market intensifies.
American Airlines Stock Faces Tuesday Test After 12% Run

American Airlines Stock Faces Tuesday Test After 12% Run

25 May 2026
American Airlines shares closed at $13.85 Friday, up 12.5% from the previous week, as oil prices dropped nearly 7% Monday amid U.S.-Iran talks. Markets were closed Monday for Memorial Day. CEO Robert Isom will speak at Bernstein’s conference Wednesday. Trading volume Friday reached 99.3 million shares, well above the three-month average.
D-Wave Shares Climb After $100 Million U.S. Quantum Deal Adds Washington as Shareholder

D-Wave Stock Gets $100 Million Government Boost, Faces Test After Holiday

25 May 2026
D-Wave Quantum shares closed at $29.40 Friday after surging on news of a possible $100 million CHIPS Act grant that would involve issuing stock to the U.S. government. The stock traded between $25.61 and $31.54, with volume at 141.7 million shares. U.S. markets are closed Monday for Memorial Day. Investors await details on the grant, potential dilution, and D-Wave’s investor day on June 1.
Go toTop